Mein Urin hatte gestern doch Recht mit NEWS, zwar nicht vorbörslich sondern nachbörslich aber immerhin. Mal sehen wie die Amis heute um 15.30 Uhr darauf reagiern.
Das es gestern runter ging ist schade, aber ich denke heute geht es dafür umso deutlicher rauf !
In Raging Bull wird diese Nachricht durchwegs sehr positiv aufgenommen. Der neue Director russischer Abstammung wird sehr gute Verbindungen bezogen auf einen der angestrebten Weltmärkte- Russland herstellen können !
Calypte Appoints New Board Member
4/6/2004 5:43:00 PM
Maxim A. Soulimov, Director of Legal Affairs of Global Corporate Ventures Limited, Appointed to the Company's Board of Directors
ALAMEDA, Calif., Apr 6, 2004 /PRNewswire-FirstCall via COMTEX/ -- Calypte Biomedical Corporation ( CYPT ) a company engaged in developing rapid tests for HIV diagnosis and the developer and marketer of the only two FDA- approved HIV-1 antibody tests that can be used on urine samples, today announced that its Board of Directors has appointed Maxim A. Soulimov as a member of the Company's Board of Directors.
Maxim A. Soulimov was appointed to the Company's Board on April 2, 2004 pursuant to an August 2003 agreement between the Company and Marr Technologies BV ("MTBV") in which MTBV purchased $2.5 million of the Company's common stock and the Company agreed to grant MTBV the right to appoint two mutually- agreeable representatives to the Board. MTBV is currently the Company's largest stockholder, holding in excess of 28% of the Company's outstanding common stock. Since November 2002, Mr. Soulimov has served as Director of Legal Affairs of Global Corporate Ventures Limited ("GCVL") of London, a company providing consultancy services to a variety of private investors including MTBV and its affiliates. From April 2000 through October 2002, Mr. Soulimov served as in-house legal counsel for Lukoil Europe Limited and Lukoil Europe Holdings Limited, private companies involved in the management of all Lukoil downstream companies outside the Russian Federation. From September 1997 to April 2000, Mr. Soulimov served as Trainee and then as Assistant Solicitor in the London firm of Norton Rose Solicitors. Mr. Soulimov holds a Degree in Modern Languages from Tver State University in Russia and an LLB Law degree from University of Hertfordshire in the United Kingdom.
Dr. J. Richard George, President and CEO of Calypte stated, "We are pleased to welcome Mr. Soulimov to our Board and look forward to his knowledge and guidance as we expand our marketing into Russia, where his business experience could prove to be a valuable asset."
Tony Cataldo, Executive Chairman of Calypte stated, "As Calypte focuses on the emerging HIV epidemic countries including China and Russia, Mr. Soulimov's experience in cross border mergers and acquisitions, restructuring, corporate finance and governance in Western and Eastern Europe may play a very vital role in Calypte's growth in those areas of the world."
About Calypte Biomedical:
Calypte Biomedical Corporation, headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of in vitro diagnostic tests, primarily for the detection of antibodies to Human Immunodeficiency Virus (HIV), and other sexually transmitted and infectious diseases. Calypte's currently marketed laboratory-based tests include an enzyme immunoassay (EIA) HIV-1 antibody screening test and an HIV-1 antibody western blot supplemental test, the only two FDA-approved HIV-1 antibody tests for use on urine samples, as well as an FDA-approved serum HIV- 1 antibody western blot supplemental test. Calypte is actively engaged in developing new test products for the rapid detection of HIV and other infectious diseases. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other infectious diseases may make important contributions to public health.
Investor Relations Contact:
Tim Clemensen
212-843-9337
email: tclemensen@rubensteinir.com
SOURCE Calypte Biomedical Corporation
Grüße
Kade_I
|
